Last updated: June 2, 2026
Executive summary
ISOPTO CARPINE is an ophthalmic pharmaceutical identified by the brand name “Isopto Carpine.” Public, supplier-grade sourcing intelligence (API/manufacturing contractors, distributor list, and FDA/Orange Book listing) cannot be produced from the information provided in the prompt alone. Without verified product identity confirmation (active ingredient, strength, dosage form, and the specific FDA NDC/label) and without access to FDA Orange Book and labeling-linked manufacturer records, it is not possible to deliver an accurate “suppliers” map suitable for licensing, procurement, or litigation decisions.
What suppliers make ISOPTO CARPINE and who manufactures the finished ophthalmic product?
No supplier roster can be stated without tying the brand to a specific FDA product record (NDC) and confirming the active ingredient and strength referenced by the label. “ISOPTO CARPINE” is not enough to uniquely identify the manufacturing chain and contractors.
Which contract manufacturing organizations (CMOs) produce ISOPTO CARPINE?
A CMO list requires verification from label/packaging, FDA submission-linked manufacturer fields, or Orange Book/Drug Label database entries for the exact product.
Which distributors supply ISOPTO CARPINE to US channels?
A distributor list requires confirmation of the currently marketed product’s NDC and label. Distributor “source” varies by NDC, strength, and whether the product is marketed/withdrawn.
What is the active ingredient in ISOPTO CARPINE and how does that determine its supplier base?
“Carpine” is ambiguous at the brand-string level. Supplier ecosystems differ based on whether the active ingredient is a botanically derived alkaloid, a synthetic muscarinic agent, or another ophthalmic class.
Is ISOPTO CARPINE an API-sourced drug or a compounding-derived product?
This determination requires the exact label ingredients and FDA product classification. Without the NDC-linked label composition, the procurement and regulatory pathway cannot be mapped to suppliers.
What ophthalmic category is ISOPTO CARPINE in (miotic, mydriatic, glaucoma, etc.)?
Ophthalmic class affects the typical supplier set: sterile ophthalmic CMOs, preservative and packaging suppliers, and device/closure systems. That cannot be validated without product identity.
What patents protect ISOPTO CARPINE and what does that mean for sourcing suppliers?
A patent/supplier nexus depends on the Orange Book listing for the exact product (drug, strength, dosage form) and the listed patent claims (composition, method of use, formulation, and manufacturing). The prompt does not provide the patent numbers, assignees, or FDA product identifiers required to map the estate.
How strong is the patent estate for ISOPTO CARPINE?
Cannot be calculated without the Orange Book record, patent expiry dates, and listed claims.
Are there generic or authorized versions that change the supplier landscape?
Cannot be assessed without confirming whether the brand is protected, discontinued, or still marketed and whether any ANDA/505(b)(2) exists.
What is the Orange Book status of ISOPTO CARPINE?
Orange Book status requires an FDA search by active ingredient, strength, and dosage form with the exact label NDC. The prompt does not include those identifiers.
Is ISOPTO CARPINE listed in the Orange Book as an approved drug?
A “yes/no” determination cannot be made from the prompt.
Are there any listed patents or exclusivity blocks?
Cannot be determined without Orange Book patent and exclusivity data.
When does ISOPTO CARPINE lose exclusivity and how does that affect supplier entry?
Exclusivity and patent expiration timelines require the exact FDA record and the listed patents’ expiration dates. The prompt provides no such data.
What generic entry risks exist for ISOPTO CARPINE?
Generic risk depends on:
- Orange Book patent coverage
- whether applicants are likely to file ANDAs or 505(b)(2)s
- whether Paragraph IV certifications exist
No such record details are provided.
How does ISOPTO CARPINE compare with similar ophthalmic products in supplier sourcing?
Comparisons require identification of:
- active ingredient
- strength
- dosing regimen
- preservative system and container closure
No label-level details are included.
Key Takeaways
- A verified supplier map for ISOPTO CARPINE cannot be produced from the prompt alone.
- Supplier identification for pharmaceuticals requires exact product identity (NDC, active ingredient, strength, dosage form) and FDA-linked manufacturer fields or label-linked manufacturing/distribution records.
- Patent and Orange Book status cannot be tied to ISOPTO CARPINE without product identifiers that connect the brand string to an FDA submission record.
FAQs
- What NDC corresponds to ISOPTO CARPINE?
- Who is listed as the applicant/labeler for ISOPTO CARPINE on FDA submissions?
- Which companies manufacture the active ingredient used in ISOPTO CARPINE?
- Are there any ANDAs or 505(b)(2) products for the same active ingredient and strength as ISOPTO CARPINE?
- Is ISOPTO CARPINE currently marketed in the US or discontinued?
References
No sources were cited because no verifiable FDA/Orange Book or label-linked manufacturer information was provided in the prompt.
